Sex: U
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Moderate injection site pain interfering with activity/ Significant injection site tenderness (tenderness during rest); Moderate injection site redness; Moderate injection site swelling; Severe fatigue with significant interference with activity; Moderate muscle pain with some interference with activity; Joint pain with some interference with activity; Headache that prevented daily activity OR required any use of a prescription pain reliver; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/ Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling) and FATIGUE (Severe fatigue with significant interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/ Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), FATIGUE (Severe fatigue with significant interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), ARTHRALGIA (Joint pain with some interference with activity) and HEADACHE (Headache that prevented daily activity OR required any use of a prescription pain reliver). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/ Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), FATIGUE (Severe fatigue with significant interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), ARTHRALGIA (Joint pain with some interference with activity) and HEADACHE (Headache that prevented daily activity OR required any use of a prescription pain reliver) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       No concomitant and treatment medications were reported.  The patient experienced events anytime during the 2 days after vaccination which were Thursday, 21-Dec-2023 and Friday, 22-Dec-2023.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:Same reporter